(FTQI) First Trust Nasdaq BuyWrite - Ratings and Ratios
Equity Securities, Call Options
Description: FTQI First Trust Nasdaq BuyWrite
The First Trust Nasdaq BuyWrite Income ETF (NASDAQ:FTQI) is an actively managed exchange-traded fund that employs a hybrid investment strategy, combining equity ownership with a call option writing strategy on the Nasdaq-100 Index. By selling call options, the fund generates income, which is then distributed to its shareholders, making it an attractive option for income-seeking investors.
The funds investment strategy involves holding a portfolio of equity securities listed on U.S. exchanges, while simultaneously writing (selling) U.S. exchange-traded call options on the Nasdaq-100 Index with expirations of less than one year. The call options are typically written at-the-money to out-of-the-money, indicating a conservative approach to managing potential upside potential and downside risk. The funds AUM of $604.30M USD signifies a sizeable presence in the market, allowing for a relatively stable source of income.
From a technical analysis perspective, the funds price is currently at $19.47, with its 20-day SMA at $19.31, indicating a bullish trend. The 50-day SMA at $18.85 and 200-day SMA at $19.21 further reinforce the positive trend. The Average True Range (ATR) of 0.16, equivalent to 0.83%, suggests relatively stable price movements. Given the 52-week high and low of $20.46 and $16.49, respectively, the fund is currently trading near the lower end of its recent range, suggesting potential for growth.
Based on the available technical and fundamental data, a forecast for FTQI could be constructed. With the current price at $19.47 and the 20-day SMA at $19.31, a potential target price could be the 52-week high of $20.46, representing a 5% upside. However, the funds income generation strategy and the overall market conditions will play a significant role in determining its future performance. If the Nasdaq-100 Index remains stable or experiences moderate growth, FTQIs strategy of writing call options could continue to generate steady income, supporting the funds price. Conversely, a significant downturn in the Nasdaq-100 Index could negatively impact the funds performance.
Additional Sources for FTQI ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
FTQI ETF Overview
Market Cap in USD | 604m |
Category | Derivative Income |
TER | 0.75% |
IPO / Inception | 2014-01-06 |
FTQI ETF Ratings
Growth Rating | 58.9 |
Fundamental | - |
Dividend Rating | 96.4 |
Rel. Strength | -4.79 |
Analysts | - |
Fair Price Momentum | 20.35 USD |
Fair Price DCF | - |
FTQI Dividends
Dividend Yield 12m | 11.54% |
Yield on Cost 5y | 17.11% |
Annual Growth 5y | 29.75% |
Payout Consistency | 97.1% |
Payout Ratio | % |
FTQI Growth Ratios
Growth Correlation 3m | 97.5% |
Growth Correlation 12m | 28.1% |
Growth Correlation 5y | 89.3% |
CAGR 5y | 8.64% |
CAGR/Max DD 5y | 0.44 |
Sharpe Ratio 12m | 1.69 |
Alpha | -6.52 |
Beta | 0.930 |
Volatility | 6.69% |
Current Volume | 81.1k |
Average Volume 20d | 154.5k |
As of July 06, 2025, the stock is trading at USD 19.62 with a total of 81,100 shares traded.
Over the past week, the price has changed by +0.62%, over one month by +2.48%, over three months by +18.25% and over the past year by +7.34%.
Partly, yes. Based on ValueRay´s Analyses, First Trust Nasdaq BuyWrite (NASDAQ:FTQI) is currently (July 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 58.88 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FTQI is around 20.35 USD . This means that FTQI is currently overvalued and has a potential downside of 3.72%.
First Trust Nasdaq BuyWrite has no consensus analysts rating.
According to our own proprietary Forecast Model, FTQI First Trust Nasdaq BuyWrite will be worth about 23.8 in July 2026. The stock is currently trading at 19.62. This means that the stock has a potential upside of +21.25%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 23.8 | 21.3% |